ClinicalTrialsFinder
RecruitingNot ApplicableNCT07393165

Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism

The Effect of Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism

Sponsor

Tanta University

Enrollment

40 participants

Start Date

May 24, 2025

Study Type

INTERVENTIONAL

Conditions

Cardiac FunctionSubclinical HypothyroidismChildrenLevothyroxine

Summary

This study aims to evaluate the effect of the treatment with levothyroxine on cardiac function in children with subclinical hypothyroidism.

Eligibility

Min Age: 4 YearsMax Age: 15 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called L-thyroxine for people with cardiac function, children, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 4 Years to 15 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGL-thyroxine

Children with subclinical hypothyroidism who will receive L-thyroxine treatment in a dose of 2μg/kg/d (the smallest dose can be given) and the dose will be titrated every 4 weeks until a normal thyroid-stimulating hormone (TSH) level is maintained.

Locations(1)

Tanta University

Tanta, El-Gharbia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07393165

Related Trials

Effects of Cartoons and Mobile Games on Preoperative Anxiety and Fear in Children With Appendicitis: An RCT

NCT076402301 location

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283179 locations

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

NCT069267511 location

Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients

NCT070438941 location

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

NCT067614171 location